Drug metabolism and transport in human organs, such as in the liver, intestine, and kidney, control the concentrations of a drug and its metabolites in the circulating system and target organs in a certain period of time following drug administration. The pharmacokinetic properties will consequently determine therapeutic efficacy and influence toxicological effects. Changes of drug metabolism and pharmacokinetics may result in significant interindividual variations in therapeutic efficacy and adverse drug reactions. Therefore, understanding drug metabolism and pharmacokinetic properties is essential for drug development and clinical therapy. Growing researches in these areas also promote the development of novel approaches to implementation of personalized medicine or precision medicine. This special issue consists of a set of original research and review articles providing recentlygained information in these areas. As the guest Editors, we would like to appreciate the journal for providing us the opportunity to share the information and thank all authors for their contributions.
Cytochrome P450 (CYP or P450) enzymes are the major superfamily of phase I drug-metabolizing enzymes. Extensive studies have demonstrated the impact of hepatic P450 functions and regulation on drug metabolism and responses. However, intestinal P450-mediated drug metabolism is an important factor dictating first-pass metabolism and oral bioavailability. Fang Xie and colleagues provide an updated review on the role of intestinal P450 enzymes in drug disposition (see a story for the front cover) 1 . The utility of genetically engineered mouse models, which target the P450-reductase (CPR) on specific tissues, in defining the contribution of intestinal and hepatic P450s to drug metabolism and pharmacokinetics is also discussed. CYP2B6 is one isoform among P450 superfamily and it metabolizes 2%-10% of clinically-used drugs. William Hedrich and colleagues present an overview on key players in the regulation of CYP2B6 expression and functions and highlight recent advanced knowledge in CYP2B6-mediated drug-drug interactions . Sung-joon Cho and colleagues demonstrate that upregulation of UGT1A9 gene expression by estradiol is a transcriptional response to the activation of ERα receptor 10 . Pharmacokinetics/pharmacodynamics (PK/PD) modeling and simulation offer quantitative understanding of drug exposure and response, guide the selection of dose and dose regimen, and predict interindividual variability towards precision medicine. Xiaomei Zhuang and Chuang Lu provide an overview on the concept and methodology of physiologically based pharmacokinetic (PBPK) modeling 11 . Case studies are presented to illustrate how PBPK modeling and simulation may benefit drug discovery 12 . Xi-ling Jiang and colleagues describe the development of a new mechanism-based PK/PD model to characterize the thermoregulatory effects of serotonergic drugs in mouse models, which may serve as a new framework for the investigation of thermoregulatory or other neuropharmacological effects of serotonergic agents 13 . Distribution of a drug to target tissues is essential to achieve therapeutic effects, while production of reactive metabolites may provoke xenobiotics-induced tissue and organ damage. Hong Shen and colleagues demonstrate tissue distribution and tumor uptake of a folate receptor-targeted, anticancer agent epothilone folate conjugate in xenograft tumor mouse models following systemic administration 14 . Pengcheng Wang and colleagues provide an overview on the metabolic pathways of isoniazid and their possible associations with isoniazid-induced liver injury 15 . In addition, Jonathan Choiniere and Li Wang provide a mini-review on the impact of environmental arsenic on gut microbe and possible link to arsenic-induced carcinogenesis 16 . We hope this special issue would serve as a valuable information resource for our readers to gain more knowledge in the fields of drug metabolism and pharmacokinetics.
